Introduction and Objective: Residing in disadvantaged neighborhoods is linked to negative health outcomes. We aimed to assess if neighborhood disadvantage, measured by the area deprivation index (ADI), predicts glycemic outcomes and development of complications in youth-onset type 2 diabetes (T2D).Methods: We extracted data from 2014-2024 from the University of California (UC) Health Data Warehouse which […]
Read MoreCategory: Diabetes
1184-P: Substance Use in Young Adults with Type 1 Diabetes (T1D) in a Pediatric Clinic
Introduction and Objective: Little is known regarding cannabis (THC) and alcohol (EtOH) use in young adults with T1D.Methods: In this cross-sectional study, participants 18-26 years old with T1D in a pediatric clinic were asked study-designed questions to assess THC and EtOH use and knowledge of their glycemic impacts. Respondents were classified by THC and EtOH […]
Read More1549-P: Reprogramming Regulatory T Cells as a Strategy to Rescue Obesity-Driven Insulin Resistance and Fatty Liver Disease
Introduction and Objective: Adipose tissue (AT) immunoregulatory T cells (Tregs) are major determinants of systemic metabolism. In the lean phenotype, Tregs protect against inflammation and maintain homeostasis in AT. However, their abundance profoundly decreases in obesity, leading to inflammation, insulin resistance, and other inflammation-driven comorbidities. The transcription factor forkhead box protein P3 (Foxp3) is essential […]
Read More1151-P: Continuous Glucose Monitoring (CGM) User Experience in Pediatric Hospital Diabetes Management
Introduction and Objective: Guidelines endorse CGM use during hospitalizations with proper support. However, barriers and facilitators for optimal implementation in the pediatric hospital setting are unknown. We aimed to evaluate user experiences before and after implementing a pediatric hospital CGM policy.Methods: In September 2024, we implemented a hospital policy to support using personal CGM to […]
Read More1020-P: Evaluating Glycemic Benefits of an AI-Driven Glucose Prediction App via Digital Twin Technology
Introduction and Objective: AI-driven glucose predictions help CGM users manage glucose levels more proactively. The Accu-Chek® SmartGuide Predict app notifies of low glucose levels within 30 minutes (LGP), nighttime hypoglycemia risk (NLP), and provides a continuous 2-hour glucose forecast (GP). This study evaluates the potential glycemic benefits of the app via in-silico analysis.Methods: Using UVa’s […]
Read More1245-P: Where You Live Matters—Association between Socioecological Factors and Gestational Diabetes Mellitus Risk in Australia
Introduction and Objective: Gestational diabetes mellitus (GDM) risk varies by area and is potentially associated with social disparity and variation in the built environment. There remains limited evidence examining the association between socio-ecological factors and GDM risk. This study examined the association between socio-ecological factors and GDM risk at local area level over time in […]
Read More910-P: SGLT2 Inhibitor Prescribing among Patients with Diabetes and Chronic Kidney Disease or Heart Failure in a Primary Care Network
Introduction and Objective: SGLT-2 inhibitors (SGLT-2i) reduce heart failure (HF) hospitalization among HF patients and slow kidney disease progression and lower cardiovascular risk among patients with chronic kidney disease (CKD). We estimated the proportion of patients with type 2 diabetes and either HF or CKD with an active prescription for an SGLT2i and identified factors […]
Read More911-P: Comparative Effectiveness of Empagliflozin vs. DPP-4i on MACE, HHF, and Mortality across Demographic Factors
Introduction and Objective: Clinical trials were not powered to examine if the cardiovascular (CV) benefits of empagliflozin (EMPA) in patients with type 2 diabetes (T2D) are consistent across demographic factors.Methods: Using Medicare data (2014-2020), we compared 1:1 propensity score-matched patients aged ≥65 years with T2D initiating EMPA vs DPP4i for MACE, hospitalization for heart failure […]
Read More904-P: Hospitalization Is a Risk Factor for SGLT2i Discontinuation
Introduction and Objective: SGLT2i have major cardiorenal benefits for people with type 2 diabetes. While some guidelines recommend temporarily withholding SGLT2i during hospitalization, limited evidence suggests many people may not restart SGLT2i following discharge. We examined if hospitalization was a risk factor for SGLT2i discontinuation, and if this differed to other diabetes therapy (DPP-4i) not […]
Read More700-P: Quality of Life in Youth and Young Adults (YYA) with Type 1 Diabetes (T1D) That Experience Device-Related Skin Reactions
Introduction and Objective: Diabetes device use in T1D is associated with improved clinical outcomes. However, many people experience device-related skin reactions. Our aim was to assess psychosocial outcomes between YYA with T1D that experience device-related skin reactions and those that do not.Methods: YYA (2-25 years) with T1D that use diabetes devices completed an in-house developed […]
Read More